Spots Global Cancer Trial Database for ADC-1013 First-in-Human Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ADC-1013 First-in-Human Study
Official Title: A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013
Study ID: NCT02379741
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or intravenously (as repeated doses directly into a vein) in patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Center for Cancer Research, Department of Oncology, Herlev Hospital, Herlev, , Denmark
Kliniska prövningsenheten (KPE), Karolinska University Hospital, Solna, Stockholm, Sweden
Department of Oncology, Uppsala University Hospital, Uppsala, , Sweden
Department of Oncology, Queen Elisabeth Hospital, Edgbaston, Birmingham, United Kingdom
The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom
Contact Details
Name: Per Norlén, MD, PhD
Affiliation: Alligator Biosciene AB, Sweden
Role: STUDY_DIRECTOR
Name: Dorte Nielsen, MD, PhD
Affiliation: Department of Oncology Herlev Hospital, Denmark
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
